Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects

Background: Inflammatory markers are increased in chronic obstructive pulmonary disease (COPD) and are hypothesised to play an important part in muscle dysfunction and exercise intolerance. Methods: The Health Aging and Body Composition (Health ABC) study is a prospective observational cohort of well functioning individuals aged 70–79 years. A cross sectional analysis of the baseline data was conducted to examine the association between inflammatory markers and ventilatory limitation, muscle strength, and exercise capacity. These associations were compared in participants with and without obstructive lung disease (OLD). Results: Of the 3075 participants enrolled in the Health ABC cohort, OLD was identified by spirometric testing in 268 participants and 2005 participants had normal spirometric results. Of the participants with OLD, 35%, 38%, and 27% participants had mild, moderate, and severe OLD, respectively. Participants with OLD had lower quadriceps strength (102.5 Nm v 108.9 Nm, p = 0.02), lower maximum inspiratory pressure (64.7 cm H2O v 74.2 cm H2O, p<0.0001), higher systemic interleukin (IL)-6 levels (2.6 pg/ml v 2.2 pg/ml, p<0.0001), and higher C-reactive protein (CRP) levels (3.5 mg/l v 2.5 mg/l, p<0.0001) than those with normal spirometry. In participants with OLD and those with normal spirometry, forced expiratory volume in 1 second (FEV1) was associated with IL-6 (adjusted regression coefficients (β) = −5.3 (95% CI −9.1 to−1.5) and −3.1 (95% CI −4.3 to −1.9), respectively). IL-6 and TNF were also associated with quadriceps strength among participants with OLD and those with normal spirometry (β = −6.4 (95% CI −12.8 to −0.03) and −3.4 (95% CI −5.4 to −1.3), respectively, for IL-6 and β = −10.1 (95% CI −18.7 to −1.5) and −3.8 (95% CI −7 to −0.6), respectively, for TNF). IL-6, quadriceps strength, and maximum inspiratory pressures were independent predictors of reduced exercise capacity in both groups. Conclusions: In well functioning elderly subjects with or without OLD, IL-6 is associated with reduced FEV1, quadriceps strength, and exercise capacity.

[1]  J. Minna,et al.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.

[2]  J. Chamberlain.  Cachexia in cancer--zeroing in on myosin. , 2004, The New England journal of medicine.

[3]  Jeffrey S. Damrauer,et al.  Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. , 2004, The Journal of clinical investigation.

[4]  F. Sciurba.  Physiologic similarities and differences between COPD and asthma. , 2004, Chest.

[5]  A Senthilselvan,et al.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.

[6]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[7]  M. Decramer,et al.  CHRONIC OBSTRUCTIVE PULMONARY DISEASE Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I , 2003 .

[8]  B. Celli,et al.  Muscle Strength and Exercise Kinetics in COPD Patients with a Normal Fat‐Free Mass Index Are Comparable to Control Subjects. , 2003, Chest.

[9]  D. Mannino,et al.  Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study , 2003, Thorax.

[10]  B. Hedblad,et al.  Lung Function and Cardiovascular Risk: Relationship With Inflammation-Sensitive Plasma Proteins , 2002, Circulation.

[11]  N. Chavannes,et al.  Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. , 2002, American journal of respiratory and critical care medicine.

[12]  H. Westerblad,et al.  Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. , 2002, American journal of respiratory and critical care medicine.

[13]  S. Kritchevsky,et al.  Leg Muscle Mass and Composition in Relation to Lower Extremity Performance in Men and Women Aged 70 to 79: The Health, Aging and Body Composition Study , 2002, Journal of the American Geriatrics Society.

[14]  A. Newman,et al.  Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[15]  F. Maltais,et al.  Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. , 2001, American journal of respiratory and critical care medicine.

[16]  A. Newman,et al.  Measuring Fitness in Healthy Older Adults: The Health ABC Long Distance Corridor Walk , 2001, Journal of the American Geriatrics Society.

[17]  A. Ionescu,et al.  Inflammatory response and body composition in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[18]  P. Ridker.  Role of inflammatory biomarkers in prediction of coronary heart disease , 2001, The Lancet.

[19]  Yi-Ping Li,et al.  Cytokines and oxidative signalling in skeletal muscle. , 2001, Acta physiologica Scandinavica.

[20]  Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. , 2001, The Journal of clinical endocrinology and metabolism.

[21]  R. Casaburi.  Skeletal muscle dysfunction in chronic obstructive pulmonary disease. , 1999, Medicine and science in sports and exercise.

[22]  H. Saito,et al.  The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor- α System in Patients with Chronic Obstructive Pulmonary Disease , 2000 .

[23]  H. Saito,et al.  The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[24]  N. Hopkinson,et al.  Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. , 2009, American journal of respiratory and critical care medicine.

[25]  G. Thorgeirsson,et al.  Effects of Leisure-Time Physical Activity and Ventilatory Function on Risk for Stroke in Men: The Reykjavk Study , 1999, Annals of Internal Medicine.

[26]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[27]  F. Maltais,et al.  Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[28]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[29]  B. Beutler,et al.  The tumor necrosis factor ligand and receptor families. , 1996, The New England journal of medicine.

[30]  R. Rogers,et al.  Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. , 1996, American journal of respiratory and critical care medicine.

[31]  N. Jones,et al.  Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. , 1995, American journal of respiratory and critical care medicine.

[32]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[33]  E. Metter,et al.  Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. , 1995, American journal of respiratory and critical care medicine.

[34]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[35]  T. Sayers,et al.  Relationship of TNF to interleukins. , 1992, Immunology series.

[36]  C. Corrigan,et al.  The roles of inflammatory cells in the pathogenesis of asthma and of chronic obstructive pulmonary disease. , 1991, The American review of respiratory disease.

[37]  P. Limburg,et al.  Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. , 1991, Biochimica et biophysica acta.

[38]  D. Reed,et al.  Smoking, pulmonary function, and mortality. , 1990, Annals of epidemiology.

[39]  A. Siegelaub,et al.  Lung function and risk of myocardial infarction and sudden cardiac death. , 1976, The New England journal of medicine.